Investigator Ticiana Leal, MD, said the the phase III LUNAR study met its primary endpoint and demonstrated a statistically significant 3-month improvement in median overall survival versus the standard of care. Read more
Dr. Sharyn Katz and colleagues summarize key recommendations for improving imaging quality in malignant pleural mesothelioma. Read more
Dr. Roy Herbst said the results reinforce adjuvant osimertinib as the standard of care for patients with resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer and highlight the importance of early biomarker testing. Read more
During ASCO’s 2023 Annual Meeting investigators shared findings from several neoadjuvant studies, including KEYNOTE-671 and Neotorch, which showed improved EFS with pembrolizumab and toripalimab, respectively. Read more
Is “resectability” based on radical resection criteria still valid in the era of neoadjuvant immunochemotherapy? ILCN’s editors say the term needs to be revisited and probably redefined based on a tumor’s status before treatment and after neoadjuvant treatment. Read more
During a recent interview with ILCN, Prof. Swanton reviewed the possible mechanisms at play when particulate matter triggers cancer growth and discussed new data that sheds additional light on the process. Read more
Investigator Dr. John Heymach says the positive phase 3 data may lead to a potential new treatment option for patients with resectable NSCLC. Read more
In a recent interview, Staging and Prognostic Factors Committee Chair Dr. Hisao Asamura provides an update on efforts to further refine the system. Read more
Adding to the discussion, Drs. David Ball, Daniel Steinfort, and Susan Harden propose alternative approaches for the complex task of improving nodal staging. Read more
ILCN Associate Editors Drs. Suresh Senan and Witold Rzyman add clinical perspective to surveillance frequency discussion. Read more